Monocarboxylate Transport 2 - Blocking Peptide

  • Catalog name: X2372B
  • Supplier name: nordc
  • Size: 50 μg
  • Price: 168.00€
  • Category Proteins & Peptides
  • Long description Functions as a proton-linked monocarboxylate transporter and catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. MCT2 is a very high affinity pyruvate transporter. MCT2 is a cell membrane; Multi-pass membrane protein with high expression in testis, moderate to low expression in spleen, heart, kidney, pancreas, skeletal muscle, brain and leukocytes. The normal expression of MCT2 is restricted to low levels of expression in normal tissues, but is widely expressed in cancer cells.
  • Antibody come from C terminal recombinant protein (~70aa) which does not overlap with clone 1G12 epitope)
  • Other description Provided as solution in phosphate buffered saline with 0.08% sodium azide.
  • Clone not specified
  • Antigen-antibody binding interaction Monocarboxylate Transport 2 - Blocking Peptide
  • Antibody is raised in Rabbit
  • Antibody's reacts with Human
  • Antibody's reacts with these species This antibody doesn't cross react with other species
  • Antibody's specificity No Data Available
  • Application Western blot
  • Antibody's suited for Antibody can be used for immunohistochemistry on paraffin-embedded tissues (10 µg/ml) and Western blotting (5-10 µg/ml). Optimal concentration should be evaluated by serial dilutions.
  • Storage -80ºC
  • Relevant references 1. Lai, J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47, 1211-1222._x000B__x000B__x000B__x000B_2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230._x000B__x000B__x000B__x000B_3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223._x000B__x000B__x000B__x000B_4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394._x000B__x000B__x000B__x000B_5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224._x000B__x000B__x000B__x000B_6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906._x000B__x000B__x000B__x000B_7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711._x000B__x000B__x000B__x000B_8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990._x000B__x000B__x000B__x000B_9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326.
  • Protein number see ncbi
  • Warnings This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
  • Test You can block the antibody by the specific target amino acid sequence of peptide.
  • Properties blocking peptide